Navigation Links
Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
Date:11/12/2009

THE WOODLANDS, Texas, Nov. 12 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS). Top-line results showed that treatment with one gram of LX1031 four times daily produced a statistically significant improvement in global assessment of relief of IBS pain and discomfort over the four-week dosing period as compared to placebo (p=0.0465). Improvements in global assessment parameters also corresponded with statistically significant improvements in stool consistency. Notably, increased clinical response correlated with a greater reduction in serotonin synthesis as reflected by measures of urinary 5-HIAA, a breakdown product of serotonin.

"Treatment with LX1031 reduced symptoms of IBS in this clinical trial, and holds promise for patients with this disease," said Dr. Brian Zambrowicz, chief scientific officer at Lexicon. "We believe the fact that the clinical benefit was correlated to the reduction in the 5-HIAA biomarker validates our therapeutic strategy of inhibiting TPH as a novel treatment option for patients with IBS. The overall safety and efficacy profile observed to date supports further development of this novel mechanism in IBS."

The Phase 2 clinical trial, which began at the end of December 2008, was a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1031 and its effects on symptoms associated with IBS. The study included 155 patients with either diarrhea-predominant IBS or mixed IBS. Two dose levels were evaluated: a 250 mg dose and a 1,000 mg
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Announces Completion of Public Offering of Common Stock
2. Lexicon Announces Pricing of Common Stock in Public Offering
3. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
4. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
6. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
7. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
8. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
9. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
10. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
11. WIFH Atlanta Announces Breakthrough Technique in Laser Hair Removal for Ethnic Skin Types
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... December 15, 2014 Investor-Edge has initiated ... ZGNX ), Eli Lilly and Company (NYSE: LLY ... SNY ), and Novartis AG (NYSE: ... accessed at: http://investor-edge.com/register . On Friday, December ... the Dow Jones Industrial Average lost 1.79%, to finish the ...
(Date:12/15/2014)... LONDON and BOSTON , ... the leading GPCR structure-guided drug discovery and development company, ... patents in the United States ... of these patents in the US significantly strengthens the ... the major pharmaceutical markets. The suite of ...
(Date:12/13/2014)... Ala. , Dec. 12, 2014 ... purchased the HiSeq X Ten sequencing system manufactured ... enable HudsonAlpha to produce and analyze genomic data ... stems from the Institute,s commitment to research programs ... The HiSeq X Ten provides unprecedented capacity, speed ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... YORK, April 20, 2011 Reportlinker.com announces that a ... Successful Strategies for Drug Repositioning ... Introduction This report Highlights ... to drug development. The success of the approach is ...
... Sagent Pharmaceuticals (Nasdaq: SGNT ) announced the ... of the offering has been increased from the previously announced ... stock at a price to the public of $16.00 per ... NASDAQ Global Market on April 20, 2011 under the ticker ...
Cached Medicine Technology:Reportlinker Adds Successful Strategies for Drug Repositioning 2Reportlinker Adds Successful Strategies for Drug Repositioning 3Reportlinker Adds Successful Strategies for Drug Repositioning 4Sagent Pharmaceuticals Upsizes and Prices Initial Public Offering 2
(Date:12/17/2014)... HealthDay Reporter TUESDAY, Dec. 16, ... approaching, a new study reveals that states that routinely perform ... drivers on their roads. The finding suggests that states ... to deter inebriated revelers from getting behind the wheel in ... passed regarding drinking and driving," said study lead author James ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Veretekk.com, Inc. ... JM Ocean Avenue. JM Ocean Avenue has secured ... Veretekk online automated marketing system. JM Ocean Avenue ... 2014 merger of Ocean Avenue and JM International, with ... $2 Billion per year company. , “After nearly 2 ...
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device ... North and South America, Europe, the Middle East, Asia ... for its 2015 Medical Device Industry Survey. Each year, ... business and market trends as well as regulatory and ... areas including:, , Overall prospects for ...
(Date:12/15/2014)... For the second year in a row, ... Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra Ulos Batak ... at number 10. This is the first year that any ... is ranked on quality, value, and other aspects, including certifications ... of 100, and at $17.99 for 12-ounces, was also the ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... CHAPEL HILL -- When pregnant women are at high risk ... has been shown to reduce the babys chances of having ... multiple injections of corticosteroids, and a new study shows that ... of cerebral palsy among children of these mothers. , Our ...
... the great questions of neurobiology, how the brain is ... a young French scientist in an award winning project ... European Heads of Research Councils (EuroHORCS). Sonia Garel ... annually to young scientists, to pursue her ground breaking ...
... to low-glycemic carbs prevents the lethal illness, study finds ... in quick-burning carbohydrates may cause fatty liver disease, which ... a study in mice by researchers at Children,s Hospital ... it may mean that fatty liver disease can be ...
... New guidelines on the diagnosis and management of cows ... Disease in Childhood, are set to improve the standard ... food allergy in children.1 The Guidelines for the Diagnosis ... extensively hydrolysed (eHF) and amino acid-based formulas (AAF), and ...
... been awarded a National Institutes of Health (NIH) Directors ... is one of 12 recipients nationwide to win the ... award is designed to support individual scientists of exceptional ... biomedical and behavioral research. The term pioneering is used ...
... the review of approximately 12,000 emergency diagnostic imaging exams ... the midst of our research, a vigorous national debate ... prior to independent call, said Richard B. Ruchman, MD, ... and subsequently approved a new requirement that would mandate ...
Cached Medicine News:Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:EURYI project to understand how the brain wires during embryogenesis 2Health News:Diet Change Can Curb Fatty Liver Disease 2Health News:New guidelines set to improve standard of cows' milk allergy care 2Health News:New guidelines set to improve standard of cows' milk allergy care 3Health News:Decision-making by residents on-call has 'miniscule' negative impact on patient care 2
... is a hospital grade Nd: YAG laser ... precise, reliable means for performing posterior capsulotomy, ... can be used for the treatment of ... (posterior capsulotomy), and closed-angle glaucoma (iridotomy). , ...
... Laserex Ultra Q is the fundamental capsulotmy laser ... energy delivery and provides 2855% less energy in ... mJs in contemporary systems. This technology eliminates ... the risk of IOL pitting. , , ...
... a high-end, mobile ultrasound imaging system. Its ... tremendous amount of processing power for generating ... Ultrasonix imaging systems provide excellent image quality ... Pulsed Doppler, Color Doppler Color Angio, Color ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Medicine Products: